Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS) (ARAMIS)

Clinical Trial ID NCT02200614

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting the adaptive molecular landscape of castration-resistant prostate cancer.	EMBO Mol Med	2015	0.93
2	Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.	Sci Rep	2015	0.91
3	Targeting the androgen receptor in prostate and breast cancer: several new agents in development.	Endocr Relat Cancer	2015	0.89
4	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer.	Clin Med Insights Oncol	2016	0.83
5	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.	Expert Rev Anticancer Ther	2015	0.83
6	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.	Int J Biol Sci	2016	0.81
7	New drugs in prostate cancer.	Prostate Int	2016	0.80
8	Androgen pathway resistance in prostate cancer and therapeutic implications.	Expert Opin Pharmacother	2015	0.77
9	Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.	Curr Urol Rep	2016	0.77
10	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.	Curr Opin Endocrinol Diabetes Obes	2016	0.76
11	Translational and clinical implications of the genetic landscape of prostate cancer.	Nat Rev Clin Oncol	2016	0.76
12	Exciting Therapies Ahead in Prostate Cancer.	P T	2015	0.75